trending Market Intelligence /marketintelligence/en/news-insights/trending/yjyixso3h7l4mo20c9t6dq2 content esgSubNav
In This List

Adaptimmune secures $100M funding from private equity firms

Blog

Banking Essentials Newsletter: September Edition

Blog

Beyond ESG with Climate Stress Testing: Getting Practical at Banks & Insurers

Blog

Enterprises are missing out on 24B by not optimizing cloud spending not going multicloud

Blog

Investment Research Analysts Providing Greater Coverage on Inflation


Adaptimmune secures $100M funding from private equity firms

Adaptimmune Therapeutics PLC said it had attracted a $100 million investment from a handful of private equity firms.

Adaptimmune entered an agreement with Matrix Capital Management Co. LP, New Enterprise Associates 16 LP, New Enterprise Associates 14 LP and Syncona Ltd. The firms will buy $100 million worth of the U.K.-based biopharmaceutical company's American depositary shares at $10 each.

The offering is expected to close Sept. 7, subject to customary closing conditions.

Adaptimmune said net proceeds will be used for the clinical development of its wholly owned pipeline of SPEAR T-cell candidates for treating multiple types of cancer and for other general corporate purposes.

In July, GlaxoSmithKline PLC acquired one of the cell therapy programs from Adaptimmune for about $27.5 million.

"This financing strengthens our balance sheet and extends our runway through to late 2020," Adaptimmune CEO James Noble said in a statement.